BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference

Preclinical data shows promise for gene therapy candidates for congenital adrenal hyperplasia due to 21-hydroxylase deficiency (BBP-631) and Canavan disease (BBP-812) Natural history clinical study for Canavan disease is currently enrolling IND submissions for both gene therapy product candidates anticipated in 2020 SAN FRANCISCO – October 22, 2019 – BridgeBio Pharma, Inc. (NASDAQ:BBIO) today announced […]

QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia

Data presented at the American Society of Human Genetics (ASHG) 2019 Annual Meeting Infigratinib showed improvements in nine measures of bone development in the Fgfr3Y367C/+ mouse model of achondroplasia at a low dose Observational study (The PROPEL Trial) is currently enrolling children age 2.5-10 years and planned submission of an investigational new drug application remains […]

BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition PALO ALTO – October 14, 2019 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed […]